Oscillatory calcium release and sustained store-operated oscillatory calcium signaling prevents differentiation of human oligodendrocyte progenitor cells

Richard A. Seidman¹, Heba Khattab², Jessie J. Polanco³, Jacqueline E. Broome² & Fraser J. Sim¹,²*

Endogenous remyelination in demyelinating diseases such as multiple sclerosis is contingent upon the successful differentiation of oligodendrocyte progenitor cells (OPCs). Signaling via the Gαq-coupled muscarinic receptor (M₁/₃R) inhibits human OPC differentiation and impairs endogenous remyelination in experimental models. We hypothesized that calcium release following Gαq-coupled receptor (GqR) activation directly regulates human OPC (hOPC) cell fate. In this study, we show that specific GqR agonists activating muscarinic and metabotropic glutamate receptors induce characteristic oscillatory calcium release in hOPCs and that these agonists similarly block hOPC maturation in vitro. Both agonists induce calcium release from endoplasmic reticulum (ER) stores and store operated calcium entry (SOCE) likely via STIM/ORAI-based channels. siRNA mediated knockdown (KD) of obligate calcium sensors STIM1 and STIM2 decreased the magnitude of muscarinic agonist induced oscillatory calcium release and attenuated SOCE in hOPCs. In addition, STIM2 expression was necessary to maintain the frequency of calcium oscillations and STIM2 KD reduced spontaneous OPC differentiation. Furthermore, STIM2 siRNA prevented the effects of muscarinic agonist treatment on OPC differentiation suggesting that SOCE is necessary for the anti-differentiative action of muscarinic receptor-dependent signaling. Finally, using a gain-of-function approach with an optogenetic STIM lentivirus, we demonstrate that independent activation of SOCE was sufficient to significantly block hOPC differentiation and this occurred in a frequency dependent manner while increasing hOPC proliferation. These findings suggest that intracellular calcium oscillations directly regulate hOPC fate and that modulation of calcium oscillation frequency may overcome inhibitory Gαq-coupled signaling that impairs myelin repair.

Abbreviations

2-FLY  2-Furoy-Leu-Ile-Gly-Arg-Leu-Orn-NH₂
2-PED  2-Pyridylethylamide dihydrochloride
5-HT  5-Hydroxytryptamine
Bay  Bay 60-6583 2-[[6-Amino-3 5-dicyano-4-[4-cyclopropylmethoxy phenyl]-2-pyridinyl]thio]-acetamide
CHPG  2-Chloro-5-hydroxyphenylglycine sodium salt
ET-1  Endothelin-1
MRS 2365  [(1R 2R 3S 4R 5S)-4-[6-Amino-2-(methylthio)-9H-purin-9-yl]-2 3-dihydroxybicyclo[3.1.0]hex-1yl]methyl diphosphoric acid mono ester trisodium salt
NAGly  N-arachidonoyl glycine
NF 546  4 4'-[Carboxylbis(imino-3 1-phenylene-carbonylimino-3 1-(4-methyl-phenylene) carbonylimino)]-bis(1 3-xylene-alpha alpha'-diphosphonic acid

¹Neuroscience Program, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. ²Department of Pharmacology and Toxicology, Jacob’s School of Medicine and Biomedical Sciences, University at Buffalo, 955 Main Street, Buffalo, NY 14203, USA. ³email: fjsim@buffalo.edu
Efficient central nervous system (CNS) remyelination is contingent upon successful intercellular signaling between neurons and glia that together orchestrate the processes of oligodendrocyte progenitor cell (OPC) recruitment, differentiation, and maturation into myelin-forming oligodendrocytes (OL)\(^1\). In demyelinating diseases such as multiple sclerosis (MS), the pathological environment contributes to an inhibition of OPC differentiation that limits remyelination and may contribute to subsequent permanent neurodegeneration\(^2\).

In support of this hypothesis, numerous quiescent OPCs are observed in chronic MS lesions that appear to be unable to undergo OL differentiation\(^3,4\). Following demyelination, OPCs are exposed to a complex cellular microenvironment comprising extracellular matrix and soluble factors released by a variety of sources including infiltrating immune cells, reactive glia, and endothelial cells as well as injured axons that release both soluble growth factors and neurotransmitters. Neurotransmitters activate multiple and functionally distinct receptors expressed on OPCs and OLs that may contribute to activity-dependent or so-called adaptive myelination (reviewed in\(^5\)). Following demyelination, neuronal activity promotes remyelination\(^6\) and this is regulated in part by AMPA and NMDA receptor signaling\(^7\). As such, intracellular calcium represents a common target for these activity-dependent pathways and suggests that a diverse set of neurotransmitters can induce intracellular calcium increase in glial progenitors\(^8\).

Intracellular calcium release occurs in OPCs following activation of ionotropic voltage and ligand gated channels and/or following activation of metabotropic receptors\(^9\). Muscarinic acetylcholine receptors M\(_1\) and M\(_3\) are G\(_\text{q}\)-coupled receptors (G\(_\text{q,R}\)) which also cause intracellular calcium release via phospholipase-C\(\beta\) (PLC\(\beta\)) and inositol triphosphate (IP\(_3\)) second messengers\(^10\). Genetic deletion of M\(_{13}\) receptors in OPCs delays differentiation and remyelination in animal models of experimental demyelination\(^11,12\). Furthermore, pharmacological inhibition of muscarinic receptors results in accelerated OL differentiation and remyelination in the brain and spinal cord following both toxin-induced demyelination and experimental autoimmune encephalitis (EAE)\(^13,14,15\). In primary human OPCs (hOPCs), M\(_{13}\)R signaling delays differentiation in vitro and reduces myelin production following transplantation into hypomyelinated shiverer mice\(^16\). OPCs have been shown to express numerous other G\(_\text{q,R}\)-coupled receptors including endothelin (ET) subtype B (ET\(_B\); ENDRB) receptors\(^17\), purinergic type 2Y (P2Y) receptors\(^17\), histamine type 1 (H1) receptors\(^18\), metabotropic glutamate receptors type 3 (mGluR3) and type 5 (mGluR5)\(^19\), 5-HT serotonin receptors\(^20\), sphingosine-1-phosphate receptors (SIPR)\(^21\), calcium-sensing receptors (CaSR)\(^22\), and adenosine 2B receptors\(^23\). While the precise function of these receptors remains unclear, previous reports suggest that activation of at least some of these receptors can paradoxically promote OPC differentiation. For example, in vitro findings suggest that ET receptor agonists increase OPC migration and block proliferation\(^19\). Stimulation of myelin basic protein (MBP) expression occurs via ET\(_B\) receptor activity, and activation of ET\(_A\) receptors has been found to promote remyelination in cerebellar slice culture\(^24\). Likewise, conditional deletion of SIPR causes increased OPC proliferation and reduced oligodendrocyte differentiation\(^25\), while CaSR null mice exhibit reduced MBP expression during development\(^26\). Despite these findings, the key signaling components downstream of muscarinic receptor activation that act to delay OPC differentiation and distinguish M\(_{13}\)R from other G\(_{\text{q,R}}\)-receptors have not yet been established.

Following activation of G\(_\text{q,R}\)-coupled receptors and calcium release from the endoplasmic reticulum (ER), calcium sensing STIM proteins in the ER membrane oligomerize and complex with ORAI channel proteins located in the plasma membrane. These calcium release activated calcium (CRAC) channels mediate store operated calcium entry (SOCE) that replenish depleted ER-stores through sarcoplasmic/endoplasmic reticulum ATPase (SERCA) pumps\(^27\). Successive activation of ER-calcium release and CRAC channel influx events result in characteristic oscillatory calcium transients\(^28\). Intriguingly, the frequency encoding of oscillatory calcium signaling is associated with cell-type specific activation of distinct downstream signaling and gene expression\(^29,30\). In rodent OPCs, in vitro application of a pharmacological SOCE antagonist limits platelet derived growth factor (PDGF)-dependent proliferation\(^31\). However, the mechanisms of action of these drugs are complex with additional actions on IP\(_3\) receptors, junction permeability, and transient receptor potential channels. Furthermore, while ligand-induced calcium oscillations have been observed in OL lineage cells\(^32,33,34\), a specific role of calcium oscillations in human OPCs has not yet been determined.

In this study, we hypothesized that the specific oscillatory signature of ligand activated G\(_\text{q,R}\)-receptor mediated calcium responses may be responsible for the regulation of hOPC differentiation. To this end, we identified several G\(_\text{q,R}\)-coupled receptors expressed by hOPCs and characterized the calcium response following application of receptor subtype-specific ligands. Only activation of muscarinic acetylcholine M\(_{13}\) receptors or metabotropic type 5 glutamate receptors (mGluR5) resulted in oscillatory transients in a large fraction of OPCs and persisted for several minutes following application of the ligand. Intriguingly, these ligands also reduced hOPC differentiation. We demonstrate that SOCE downstream of M\(_{13}\)R ligand activation is dependent on ER calcium sensors STIM1/2. More specifically, we found that both STIM proteins contribute to the magnitude of SOCE in human OPCs and that STIM2 regulates the oscillatory frequency of M\(_{13}\)R-induced calcium responses. Knockdown of STIM2 resulted in reduced OL differentiation and prevented the anti-differentiative effects of M\(_{13}\)R signaling in hOPCs. Lastly, using optogenetic activation of CRAC-mediated calcium flux, we demonstrate that SOCE induction is sufficient to inhibit hOPC differentiation in the absence of G\(_\text{q,R}\) signaling and that modulation of OPC proliferation and differentiation was dependent on SOCE frequency.

**Table**

| Name          | Chemical Formula                          |
|---------------|-------------------------------------------|
| Oxo-M         | Oxotremorine methiodide                   |
| PF9           | 2-(Phenylethynyl)adenosine-5′-triphosphate tetrasodium salt |
| TC-G          | 4-Methoxy-N-[[2-(trifluoromethyl)]1′-biphenyl]-4-yl]amine carbonyl-3-pyridinecarboxamide |
| TRAP-6        | Thrombin receptor activating peptide 6    |
Materials and methods

Human CD140a/PDGFRα cell preparation and culture with Gαq agonists. Fetal brain tissue samples, between 17 and 22 weeks of gestational age, were obtained from Advanced Bioscience Resources (Alameda, CA) with informed consent obtained from all donors. All research was performed in accordance with relevant guidelines/regulations. Following review by the University at Buffalo Research Subjects Institutional Review Board, the tissue acquisition and research was not deemed to involve human subjects as defined under HHS regulations 45 CFR 46, 102 (f). Forebrain samples were minced and dissociated using papain and DNase as previously described33. Magnetic sorting of CD140a/PDGFαR positive cells was performed as described34.

Plasmid construction, lentiviral generation, and titration. EF1α:GCaMP6s was described previously12. EF1α:jRCaMP1a was cloned as follows. pGP-CMV-NES-jRCaMP1a was obtained from AddGene (#61562)35. The nuclear export signal (NES) and jRCaMP1a coding region was PCR amplified: SpeI, forward′ 5′-AACACTAGTGAAAGCGTGTCGCTAG-3′; PspXI (Thermo Fisher Scientific), reverse, 5′-AAAGCT CGAGCTCTCAAAATGGTAGGTAGCTG-3′ (Thermo Fisher Scientific). PCR products were purified (Monarch PCR Cleanup Kit (NEB, #T1030S)) and restriction digested with unique 5′ SpeI and 3′ PspXI sites, and purified again. NES-jRCaMP1a digested PCR fragments were then ligated into lentiviral pTRIP-EF1α vector (a gift of Abdel Benraiss, University of Rochester)36. The plasmid pLenti-EF1α-OptoSTIM was a gift from Taeyoon Kyung (KAIST, DAJEON, Republic of Korea)37. Lentiviruses were generated as described38 and titration of EF1α:GCaMP6s and EF1α:OptoSTIM was performed as previously described39. Optimized multiplicity of infection (MOI) in hOPCs was determined for EF1α:GCaMP6s and EF1α:jRCaMP1a by infecting hOPCs and quantifying proportion of responsive cells following administration of 25 µM Oxo-M. Optimal MOI for EF1α:OptoSTIM lentivirus was determined through analysis of optimal GFP expression in infected hOPCs.

Calcium imaging using LV EF1α:GCaMP6s. Calcium imaging was performed as described previously12. GCaMP6s infected hOPCs were seeded at 4–5 × 10⁴ cells/mL and imaged 24 h after seeding. All experimental data were generated from independent experiments using individual naïve cultures of hOPCs from separate patient fetal samples. To avoid possible confounds relating to sequential application of small molecules, all cultures were used only once for imaging calcium responses and only a single dose was tested in each well, with two technical replicate imaging fields imaged simultaneously per well for each dose or condition tested. In dose response experiments, all doses per drug were tested on the same experimental day for each fetal sample preparation. Bright field and fluorescence images were acquired (10×; Olympus IX51 microscope with a Exfo X-Cite 120i response experiments, all doses per drug were tested on the same experimental day for each fetal sample preparation. In dose response experiments, all doses per drug were tested on the same experimental day for each fetal sample preparation. Bright field and fluorescence images were acquired (10×; Olympus IX51 microscope with a Exfo X-Cite 120i fluorescence imaging system). Total acquisition time was 20–30 min after the addition of ligand. To define calcium peaks and characterize the properties of ligand-induced calcium oscillations, individual cell traces were loess smoothed prior to the identification of local minima and maxima in 16-s windows. Calcium peaks were defined as maxima whose amplitude increased ≥ 0.35 fold-change above the preceding local minima. Peak amplitude was defined as the difference in fluorescence values from the calcium peak to the preceding local minima. The number of oscillations was defined as the number of peaks identified during the recording session. A responsive cell was defined as any cell with at least one peak, and an oscillatory cell as any cell with two or more peaks. Response duration was measured from the local minima prior to the first peak oscillation to the local minima following the last peak oscillation, or at the end of the time-lapse recording if an on-going calcium peak had not yet reached baseline. For oscillatory cells, frequency was calculated by dividing the total number of peak oscillations by the response duration. Area under the curve (AUC) was calculated (Mess package, v0.5.6; https://cran.r-project.org/web/packages/MESS/index.html) by subtraction of F₀ and then analyzed as integral pixel intensity above baseline beginning from the local minima preceding the first identified peak on the normalized calcium curve following ligand stimulation for the duration of the imaged response.

Raw data measurements of individual cell calcium responses were assessed for normality. Per-cell AUC and frequency measurements exhibit significant skew and were log-transformed to achieve a near normal distribution. Unless otherwise stated, a linear model was used for one-way ANOVA using drug dose as a covariate, as well as human sample to consider individual sample variability. Non-linear regression was performed using GraphPad Prism (8.0e) using a variable slope-four parameter logistic equation to model and calculate EC₅₀ for each drug. For STIM KD experiments, GCaMP6s cells were transfected with STIM siRNA and imaged 24–48 h post transfection.

Assessment of store-operated calcium entry. For direct assessment of SOCE, hOPCs were infected with LV-GCaMP6s (1 MOI) and 5 × 10⁴ cells/mL were seeding in 48-well plates and imaged the following day. To remove extracellular calcium, 15 min prior to imaging media was replaced with HBSS without phenol red, calcium, and magnesium (Corning, #21-022) (HBSS−). For all conditions, fields were imaged with a 5 s interval for at least 15 min (488 nm excitation, 400 ms exposure). Addition of the SERCA blocker Thapsigargin (Tg) or the muscarinic agonist Oxtremorine-Methiodide (Oxo-M) with or without store operated calcium entry (SOCE) channel antagonists occurred at ~1–2 min after the start of imaging. Calcium ([Ca²⁺]i) was re-introduced 10–15 min following addition of Tg or Oxo-M. Final concentrations of compounds were Tg [10 µM], or Oxo-M [25 µM], and 2-APB [50 µM] or MRS-1845 [10 µM] (final DMSO concentration did not exceed 0.15%, which did not influence [Ca²⁺]i). For quantification of SOCE, per cell calcium response curves were normal-
Figure 1. Gαq-receptor activation induces ER-Ca2+ responses and SOCE in primary human OPC. Primary fetal brain-derived PDGFβR+ hOPCs were infected with intracellular Ca2+ reporter GCaMP6s expressing lentivirus. Time-lapse microscopy of GCaMP6s fluorescence following Gαq-receptor agonist treatment was recorded and analyzed. (A) Pseudo-colored GCaMP6s fluorescence time-lapse images of oscillatory calcium transients following stimulation with Oxo-tremorine-M (Oxo-M) [2.5 µM] (top) and CHPG [2.3 mM] (bottom). (B) Shows corresponding normalized Ca2+ traces. Drug stimulation occurs at 0 s (black arrow in B) and time following drug addition is indicated in each panel. Red and green dots indicated defined local maxima and minima, respectively. Gold dots indicated defined peaks. Images shown in A after drug addition correspond to calcium peaks (red) or post-peak minima (blue) and are indicated as arrows in B. Blue lines below traces indicate the calculated response duration. (C,D) Dose–response curves of the percentage of hOPCs responding to Gαq-ligand treatment following treatment with either oxotremorine-M (Oxo-M) or CHPG (mean ± SEM, n = 3 human fetal samples, > 240 cells per biological replicate). (E,F) Dose–response curve for the log10-transformed overall area under the curve (AUC) for [Ca2+]i release per cell (mean ± SEM shown, n > 250 cells per dose, obtained from n = 3 human fetal sample). EC50 for AUC was calculated by non-linear regression for each compound (variable slope, four parameters). (G) To directly assess SOCE, GCaMP6s-expressing hOPCs were cultured in calcium-free conditions for 5–10 min prior to time-lapse microscopy. Following a 1–2 m baseline, cells were treated with thapsigargin (Tg) or Oxo-M, followed by re-addition of calcium containing solution [1.2 mM] to stimulate SOCE (green dashed lines) in the presence (middle and bottom traces) or absence (top trace) of SOCE antagonists. Calcium traces showing mean pixel intensity ± SEM (blue shading) of ≥ 44 cells from a single biological replicate. Timings for addition of Tg, Oxo-M and Ca2+–containing solution are indicated by horizontal bars above each plot. (H) Quantification of SOCE was performed by analysis of AUC of calcium influx following calcium re-addition (mean ± SEM; Tg: n = 2 human fetal sample preparations; OxoM: n = 3 human fetal sample preparations). *p < 0.05, RM one-way ANOVA with Holm–Sidak’s post-hoc test. Scale: 25 µm.

siRNA transfection. hOPCs were seeded at 5 × 10⁴ cells/mL and Lipofectamine RNAi max (Invitrogen, #13778-150) was used to transfect cells according to the manufacturer’s protocol with minor alterations. Briefly, stealth RNAi negative control duplex medium GC content (Invitrogen, #12935300) or three combined stealth RNAi against STIM1 (Invitrogen, ID #'s: HSS110308, HSS110309, HSS186144) and/or STIM2 (Invitrogen, ID #'s: HSS183972, HSS183973, HSS183974) were pooled and used for transfection. Stealth RNAi (100 nM total RNAi per well) was used to transfect hOPCs per each condition with 1.5% v/v Lipofectamine. For calcium imaging, cells were plated in 48-well plates and imaged 24 h post-transfection. In differentiation experiments, mitogen containing media was removed 24 h post-transfection (experimental day 0) and replaced with media without mitogens. Oxo-M [25 µM] was added on experimental day 0 upon removal of growth factors and on experimental day 2 during a half media change. hOPCs were fixed on experimental day 3–4 following live staining with mouse x O4 Hybridioma primary antibody [1:25]. Immuno-cytochemical analysis was performed as described previously[22]. For analysis of STIM expression, cells were plated at 5 × 10⁴ cells/mL 6-well plates and transfected after 24 h. RNA was extracted 24–48 h post-transfection for cDNA synthesis and quantitative RT-PCR analysis.

Quantitative RT-PCR analyses. Total RNA was extracted (Omega Biotek) and cDNA was synthesized using SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA). Human-specific primers for SYBR green-based PCR were designed (Table 1). Samples were run in triplicate and gene expression calculated by ΔΔCt method using GAPDH as a reference. Statistical significance was tested on log2-transformed data normalized to control using a one-sample t test assuming equal SD and compared to a hypothetical value of 100 (GraphPad Prism 8.0e).

Assessment of long-term OptoSTIM-induced SOCE. For all long-term experiments, hOPCs were seeded at a density of 2.5–3.0 × 10⁵ cells/mL into poly-ornithine and laminin coated ibidi tissue culture treated µ-slide VI 0.4 (ibidi, #80606) in mitogen containing Livelight ND media to reduce phototoxicity[46]. Cells were then imaged in an on-stage ibidi environmentally controlled chamber to maintain 37 °C, 5.0% CO2, and >60% humidity for the duration of each imaging experiment. In long-term calcium imaging experiments, hOPCs were infected with jRCaMP1a (1 MOI) and OptoSTIM (1 MOI) lentiviruses. Two fields per each of 3 µ-slide channels were then imaged at 10 x with 594 nm excitation every 20 s for 3 h to measure jRCaMP1a fluorescence calcium responses. After a 30-min no-stimulation period and for the remainder of imaging, hOPCs were stimulated with 488 nm excitation (every 5 or 30 min with 330 and 2000 ms illumination times respectively) to induce
in only a small fraction of GCaMP6-expressing hOPCs (between 1–30%). In contrast, activation of M1/3R and a detectable increase in intracellular calcium concentration measured by GCaMP6s fluorescence. However, con-

samples). Both agonists induced a dose-dependent increase in the proportion of responding cells (Fig. 1C,D). mGluR5 receptors by Oxo-M and CHPG, respectively, elicited robust responses in > 46% of hOPCs (n = 3 human

patterns of Gαq-mediated calcium responses in hOPCs, we used lentivirus to express the intracellular calcium

with Holm–Sidak’s post-hoc test for quantification of the proportion of O4+ to GFP+ cells and quantification of

subsequently analyzed in R. Briefly, a baseline curve was generated by fitting minima points under each calcium

fluorescence intensity data within the region of interest for all cells tracked across all frames was exported and

AUC was calculated for the duration of the stimulation period. Calcium traces are presented as fold change in

jRCaMP1a fluorescence values per each time-point were normalized by subtraction of the baseline curve and

calcium responses was conducted by implementing the automated tracking plugin TrackMate in ImageJ42. Mean

and µManager software. The complete imaging script is available upon request. Analysis of OptoSTIM-induced

SOCE calcium responses. A custom beanshell script was designed and implemented to facilitate multi-channel

and multi-position imaging and provide an interface between the motorized stage, fluorescent shutter (Prior),

and µManager software. The complete imaging script is available upon request. Analysis of OptoSTIM-induced

calcium responses was conducted by implementing the automated tracking plugin TrackMate in ImageJ42. Mean

fluorescence intensity data within the region of interest for all cells tracked across all frames was exported and

subsequently analyzed in R. Briefly, a baseline curve was generated by fitting minima points under each calcium

trace using the "spc-Rubberband" function (hyperSpec package). Traces were first normalized by division of the

baseline curve and loess fitted to identify responsive cells with ≥ 12.5% increase in jRCaMP1a fluorescence

within 2 min following the first OptoSTIM 488 nm pulse. For quantification of AUC, each tracked cell’s mean

jRCaMP1a fluorescence values per each time-point were normalized by subtraction of the baseline curve and

AUC was calculated for the duration of the stimulation period. Calcium traces are presented as fold change in

jRCaMP1a fluorescence from baseline, averaged across all cells per each time-point with SEM calculated. In
differentiation and proliferation experiments, OptoSTIM infected hOPCs (1 MOI) were seeded into µ-slides and

bright field imaged for 2–3 days. Following a 10–12 h baseline period, OptoSTIM activation was initiated with

488 nm stimulation at different frequencies (every 5 or 30 s with 330 or 2000 ms illumination times respectively)

for the remainder of imaging. After imaging, cells were immunostained for O4 and the number of O4+ and GFP+ cells were counted and analyzed. Repeated measures (RM) one-way ANOVA was employed with Holm–Sidak’s post-hoc test for quantification of the proportion of O4+ to GFP+ cells and quantification of morphological branching. In proliferation experiments, cell density was counted at the onset of blue light stimulation and mitotic events were identified and counted throughout the stimulation period. RM one-way ANOVA with Holm–Sidak’s post-hoc test was implemented to quantify significance in proliferative events normalized to initial densities for each condition.

Results

Gαq-receptor activation induces ER-Ca 2+ responses and SOCE in hOPC. We hypothesized that Gαq-coupled receptors would exert distinct effects on intracellular calcium responses in hOPCs and that these responses would correlate with their functional effects. Using RNA-seq of human primary PDGFRα-isolated OPCs, we determined that hOPCs expressed a diverse set of 122 GPCRs including 14 GPCRs that couple via Gαq proteins (GPCRs “GO:0004930” and PLC activating Gαq-coupled “GO:0007200”, respectively). To determine the patterns of Gαq-mediated calcium responses in hOPCs, we used lentivirus to express the intracellular calcium reporter GCaMP6s hOPCs. We next exposed independent cultures to receptor selective ligands at tenfold the

reported EC 50 concentration and measured resultant calcium responses (Fig. 1 and Table 2). All ligands induced a detectable increase in intracellular calcium concentration measured by GCaMP6s fluorescence. However, consistent with receptor heterogeneity among individual OPCs, the majority of ligands tested increased calcium in only a small fraction of GCaMP6-expressing hOPCs (between 1–30%). In contrast, activation of M 1/3R and mGluR 5 receptors by Oxo-M and CHPG, respectively, elicited robust responses in > 46% of hOPCs (n = 3 human samples). Both agonists induced a dose-dependent increase in the proportion of responding cells (Fig. 1C,D).
The extent of total calcium flux was determined by measuring the area-under-curve (AUC). AUC was defined as the area of the response above baseline beginning at the initial response until the end of the imaging session (see “Methods”). Raw AUC values were log10-normalized to achieve normality and displayed as mean ± SEM of pooled responses from > 250 cells quantified per each dose from three independent experiments using three

### Table 1. qPCR primers.

| Primer | Sequence 5′-3′ |
|--------|----------------|
| WPRED | Forward: CGCCTGCTTTATGCCTTGTAT  |
|        | Reverse: GGGCACACACTCCCTGAAAA  |
| GAPDH | Forward: GGTAAATGGCTGAGTACTACAGG  |
|        | Reverse: CCTTGGATGTGTATGGGAG  |
| STIM1  | Forward: CTCTCTTCTTTGCTCAATAATC  |
|        | Reverse: GCTGGAGTAACAGCTTGAGATAG  |
| STIM2  | Forward: CACACACACACACACTCTT  |
|        | Reverse: GCCCTCCCTCTTCCTTCTATT  |

### Table 2. Human OPC-expressed Gαq-coupled receptors differentially regulated oscillatory intracellular calcium fluctuations. RNA-seq data from human and mouse46 was used to identify Gαq-coupled receptors expressed by OPCs. FPKM values shown (mean ± SEM, n = 2 independent human fetal sample preparations). Ligands activating each receptor were identified to determine the calcium response characteristics in hOPCs. hOPCs were infected with GCaMP6s-expressing virus and exposed to various Gαq-coupled receptor ligands at doses approximately tenfold larger than reported EC50 values (or previously effective doses in rodent OPCs*). Calcium responses were recorded for at least 10 min and analyzed as described. The percentage of responding cells (at least 1 peak response ≥ 0.35 fold increase from baseline on normalized calcium trace following ligand addition), maximum response amplitude (fold change from baseline), duration of response (minutes) and percentage of responding cells displaying an oscillatory calcium response (cells with ≥ 2 identified peak responses) were determined. While Gαq-coupled LPA receptors LPAR1 and LPAR4 were detected in hOPCs, due to the lack of specific ligands we did not test these receptors. Mean ± SEM of total % responsive cells from n = 2–3 independent human fetal sample culture preparations (Oxo-M, CHPG and ET-1 data: n = 3 independent fetal sample culture preparations; data for all additional ligands: n = 2 individual fetal sample culture preparations).

| Gene Symbol | FPKM (hOPC; mOPCs) | Agonist/doses tested | Reported EC50 | % Responsive | Maximum amplitude | Duration (min) | % Oscillatory |
|-------------|---------------------|----------------------|---------------|-------------|------------------|----------------|--------------|
| CHRM3       | 16.3 ± 2.0; 0.27 ± 0.11 | Oxo-M [25 µM] | 2.5 µM75 | 67.6 ± 10.0  | 2.17 ± 0.06  | 6.1 ± 0.8  | 58.3 ± 20.5  |
| CHRM1       | 4.0 ± 0.9; 2.06 ± 0.66  | CHPG [7.5 mM] | 750 µM76 | 46.9 ± 9.7   | 0.87 ± 0.03  | 6.7 ± 0.1  | 48.6 ± 4.1   |
| GRM5        | 1.2 ± 0.004; 13.23 ± 3.63 | TC-G [1006 [350 nM] | 35 nM77 | 27.8 ± 2.3   | 0.6 ± 0.02  | 2.3 ± 0.2  | 24.8 ± 14.1  |
| S1PR1       | 3.1 ± 0.3; 34.32 ± 8.80  | TRAP-6 [8.0 µM] | 800 nM78 | 21.2 ± 13.3  | 1.0 ± 0.10  | 2.8 ± 0.5  | 38.9 ± 7.3   |
| F2R         | 26.7 ± 0.1; 23.54 ± 3.31 | PF9 [400 pM] | 36 pM79 | 19.3 ± 0.7   | 0.6 ± 0.01  | 2.3 ± 0.3  | 17 ± 10.3    |
| GPR17       | 3.6 ± 1.4; 440.98 ± 42.13 | ET-1 [150 nM] | 10 nM80 | 16.8 ± 4.3   | 1.03 ± 0.09 | 2.4 ± 0.3  | 28.8 ± 5.6   |
| EDNRB       | 17.3 ± 0.1; 292.72 ± 10.54 | MRS 2265 [12 nM] | 1.2 nM81 | 14.6 ± 8.4   | 2.9 ± 0.20  | 9.3 ± 0.9  | 48.3 ± 0.3   |
| P2RY1       | 1.0 ± 0.2; 4.94 ± 1.46 | 2-PED [560 µM] | 56 µM82 | 7.4 ± 3.7    | 0.9 ± 0.06  | 3.1 ± 0.1  | 29.2 ± 4.2   |
| HTRR2       | 0.8 ± 0.2; 0.12 ± 0.02 | 5-HT [100 µM] | 10 µM83 | 13.0 ± 12.4  | 0.7 ± 0.08  | 2.1 ± 0.1  | 14.3 ± 14.3  |
| F2RL1       | 1.3 ± 0.02; 0.10 ± 0.10 | 2-FLY [1.0 µM] | 100 nM84 | 8.5 ± 1.3    | 1.6 ± 0.16  | 11.2 ± 0.2 | 63.7 ± 7.0   |
| HRH1        | 0.4 ± 0.1; 5.01 ± 0.49 | 2-PED [560 µM] | 56 µM85 | 7.4 ± 3.7    | 0.9 ± 0.06  | 3.1 ± 0.1  | 29.2 ± 4.2   |
| GPR18       | 0.9 ± 0.4; 0.10 ± 0.10 | NAGly [10 µM] | 1 µM86 | 5.0 ± 3.9    | 1.3 ± 0.23  | 6.3 ± 3.5  | 21.8 ± 21.8  |
| ADOUR2B     | 0.6 ± 0.2; 8.79 ± 0.88 | Bay [5.8 µM] | 580 nM87 | 2.7 ± 2.7    | 0.4 ± 0.40  | 1.4 ± 1.4  | 12.5 ± 12.5  |
| P2RY11      | 0.3 ± 0.1; – | NF 546 [5.0 µM] | 500 nM88 | 1.1 ± 1.1    | 0.28 ± 0.28 | 0.9 ± 0.9  | 0.0 ± 0.0    |
that distinct patterns of calcium signaling occur following Gαq-receptor activation and that calcium signaling treatment significantly reduced complex branch formation in differentiated O4+ immature oligodendrocytes from sarco-endoplasmic reticulum Ca2+-ATPases inhibitor (SERCA) blocker43 (Fig. 1G and Supplemental Fig. S3A). Revealed expression of both calcium sensors STIM1 and STIM2 (STIM1: 8.69 ± 0.004 and STIM2: 30.0 ± 0.56; 27 ± 4% to 18 ± 5% (p = 0.006) suggesting blockade of OL maturation (Supplemental Fig. S2F). These data suggest RM One-way ANOVA with Holm–Sidak’s post-hoc test, p = 0.01, n = 5 human samples). Furthermore, CHPG responses (Table 2). Intriguingly, of those ligands which resulted in calcium transients in < 30% of cells, we often observed the majority of responses were monotonic and typically short-lived returning to baseline within 3 min following agonist application. In contrast, agonists for M1/3R and mGluR5 receptors resulted in prolonged oscillatory calcium transients which persisted for over 9 min (9.5 ± 2.0 and 11.0 ± 0.6 min, for Oxo-M and CHPG respectively; mean ± SEM, n = 3 human samples). For all doses tested, Oxo-M elicited oscillatory calcium signals in ~ 50% of all responsive cells (Supplementary Fig. S1A). In comparison, cells responsive to CHPG treatment exhibited a significant increase in the percentage of oscillatory responsive cells at higher concentrations (75 μM vs 2300 μM, RM one way ANOVA with Holm–Sidak’s post-hoc test, p < 0.05) (Supplementary Fig. S1B). The number of oscillations did not differ significantly between Oxo-M nor CHPG concentrations tested (Supplementary Fig. S1C,D). There was a significant increase in maximum amplitude with Oxo-M dose (main effect, p = 0.03), which was not observed in CHPG treated cells (Supplementary Fig. S1E,F). Both ligands induced oscillatory calcium signals with an average frequency of ~ 10 mHz (Supplementary Fig. S1G,H). As such, the calcium responses following activation of Gαq-coupled receptors were distinguishable from one another, and the similarity of prolonged oscillations in the calcium response following mGluR5 agonist treatment to M1/3R suggested that a common downstream signaling pathway may be engaged compared to other ligands. As M1/3R activation leads to a profound blockade of hOPC differentiation44, we hypothesized that the prolonged oscillatory calcium response may underlie this effect and that mGluR5 activation would therefore lead to a similar inhibition of differentiation. In addition, we predicted that EDNRB activation, which instead elicits a minimal and transient calcium response, would not influence hOPC differentiation. To test this hypothesis, we treated hOPCs with ET-1 or CHPG in the absence of mitogens and determined the effect on O4+ oligodendrocyte (OL) differentiation after 3–4 days (Supplementary Fig. S2). 150 nM and 1.5 μM ET-1 did not influence the proportion of O4+ OLs (RM One-way ANOVA with Holm–Sidak’s post-hoc test, p = 0.64, n = 2 human samples) (Supplemental Fig. S2A,B). Furthermore, ET-1 did not alter the generation of complex branched O4+ oligodendrocytes (p = 0.59) (Supplemental Fig. S2C). In contrast, treatment with the mGluR5 agonist CHPG [1.3 mM] significantly attenuated O4+ OL differentiation from 42 ± 4% to 32 ± 5% (Supplemental Fig. S2D,E); RM One-way ANOVA with Holm–Sidak’s post-hoc test, p = 0.01, n = 5 human samples). Furthermore, CHPG treatment significantly reduced complex branch formation in differentiated O4+ immature oligodendrocytes from 27 ± 4% to 18 ± 5% (p = 0.006) suggesting blockade of OL maturation (Supplementary Fig. S2F). These data suggest that distinct patterns of calcium signaling occur following M1/3R agonist stimulation and that calcium signaling downstream of Gαq-receptor activation may act to block hOPC differentiation and maturation. SOCE is activated following M1/3R agonist stimulation. Oscillatory calcium responses can be sustained following endoplasmic reticulum (ER) store release by several mechanisms including calcium recycling and, importantly, by store-operated calcium entry (SOCE) through the activation of calcium release activated channels (CRAC) (for review see46). We hypothesized that CRAC channels were activated following M1/3R Gαq-receptor activation and store depletion in hOPCs. Calcium responses in hOPCs were measured following infection with lentivirus encoding calcium reporter GCaMP6s12. To investigate whether SOCE occurs following ER Ca2+ depletion in hOPCs, we treated cells in the absence of extracellular Ca2+ with thapsigargin (Tg) [10 μM], a sarco-endoplasmic reticulum Ca2+-ATPases inhibitor (SERCA) blocker47 (Fig. 1G and Supplemental Fig. S3A). After the initial peak in calcium due to store depletion, we observed a clear SOCE associated peak following calcium reintro-duction (Fig. 1G,H and Supplemental Fig. S3B; 326 ± 67.72 AUC, n = 3 human sample, with ≥ 48 cells quantified per condition/replicate). We quantified SOCE as the area under the calcium curve (AUC) following calcium re-addition (n = 2 independent human sample preparations with ≥ 44 cells quantified per condition/replicate). We observed substantial SOCE following ER depletion with Tg (254.5 ± 51.3 AUC arbitrary units) which was nearly abolished by pre-incubation with 2-APB or MRS-1845 (Fig. 1H; RM one-way ANOVA with Holm–Sidak’s post-hoc test, p < 0.05; 2-APB: 0.2 ± 0.02; MRS: 7.1 ± 4.3). There were no differences in the initial cytosolic calcium release following Tg induced ER depletion in each condition (RM one-way ANOVA, AUC, p = 0.42). Together these results were consistent with robust SOCE in hOPCs following ER-depletion that could be blocked by pharmacological CRAC channel antagonists. To test the hypothesis that M1/3R activation leads directly to SOCE, we assessed SOCE following muscarinic agonist treatment. Similar to Tg treatment, Oxo-M [25 μM] induced robust SOCE following calcium reintroduction (Fig. 1G,H and Supplemental Fig. S3B; 326 ± 67.72 AUC, n = 3 human sample, with ≥ 48 cells quantified per condition/replicate). Likewise, pre-incubation with 2-APB similarly resulted in a substantial reduction of SOCE (Fig. 1G,H and Supplemental Fig. S3D; RM one-way ANOVA with Holm–Sidak’s post-hoc test, p = 0.037; Oxo-M + 2-APB: 9.8 ± 3.9). While not significant, we also observed a ~ 50% reduction in SOCE following pre-incubation with MRS (Fig. 1G,H and Supplemental Fig. S3F, Oxo-M + MRS: 169.3 ± 53.8, p = 0.1). As above, there were no differences in the magnitude of intracellular calcium release following ER-depletion between all Oxo-M conditions tested (RM one-way ANOVA, p = 0.2). Together, these results show that robust SOCE occurs following M1/3R induced signaling in hOPCs. STIM1/2 expression is necessary for muscarinic receptor induced SOCE. The permeability of CRAC channels are regulated by STIM calcium sensor proteins47. RNA-seq analyses of human OPcs revealed expression of both calcium sensors STIM1 and STIM2 (STIM1: 8.69 ± 0.004 and STIM2: 30.0 ± 0.56; FPKM ± SEM, n = 2) and was similar to that observed previously in mouse OPcs48 (Stim1: 13.9 ± 1.4 and Stim2: 14.9 ± 0.7). We hypothesized that the calcium sensors STIM1 and STIM2 would be directly involved in regulat-
Figure 3. Calcium sensor STIM2 regulates human OPC differentiation and is required for the anti-differentiative effect of muscarinic agonists. hOPCs were transfected with STIM1 and/or STIM2 siRNA, or control non-targeting siRNA, and 24 h later PDGF-AA and NT-3 were removed to induce oligodendrocyte differentiation. (A) Representative images of immature O4+ oligodendrocytes (green) in the presence or absence of muscarinic agonist, Oxo-M [40 μM]. (B) Quantification of the percentage of O4+ oligodendrocyte differentiation among DAPI+ cells (blue). Mean ± SEM shown (n = 4 human fetal sample culture). Differences in O4% were analyzed by RM three-way ANOVA using OxoM, STIM1, and STIM2 as factors and repeated measures across individual patient samples. Both Oxo-M and STIM2 siRNA treatment resulted in a significant effect on O4+ oligodendrocyte differentiation (OxoM: F (1, 3) = 14.31, p = 0.032 and STIM2: F (1, 3) = 28.64, p = 0.0128). *p < 0.05 and **p < 0.01 indicate pairwise Holm–Sidak post-hoc tests. (C) The percentage of dividing OPCs defined as KI-67+/DAPI+ cells following siRNA transfection was determined in each group (n = 3 human samples). Neither STIM1/2 siRNA nor Oxo-M treatment significantly influenced OPC proliferation (RM three-way ANOVA, main effects p > 0.05). Scale: 50 μm.

Intriguingly, STIM2 KD also resulted in a significant reduction in the frequency of Ca2+ oscillations (Fig. 2G; linear model with Tukey’s HSD posttest, p < 0.0001) and STIM2 (Fig. 2B; STIM2 and STIM1/2: p < 0.0001) following STIM knockdown (KD) in hOPCs. Interestingly, we also observed a small but significant decrease in STIM1 expression (p < 0.05) following STIM2 siRNA transfection, as well as a reduction in STIM2 expression following STIM1 siRNA (p < 0.01). To directly assess the role of STIM proteins in muscarinic receptor-induced SOCE, we assessed calcium influx following extracellular calcium removal and re-addition in the context of STIM1/2 KD and Oxo-M treatment. As shown above, Oxo-M stimulation which was effectively blocked by CRAC antagonist 2-APB (n = 4 independent human fetal sample preparations, RM one-way ANOVA with Holm–Sidak’s post-test, p = 0.003). STIM1 and STIM1/2 KD significantly reduced SOCE by ~40% (STIM1: p = 0.047; STIM1/2: p = 0.041) while STIM2 had no effect (p = 0.19) (Fig. 2C–E). These results suggest that STIM1 contributes to muscarinic-induced SOCE and is a key component of the endogenous hOPC CRAC apparatus. As STIM1/2 silencing may influence endogenous ER-store calcium content, we analyzed the total calcium flux (AUC) and maximum amplitude of ER calcium store depletion in response to Oxo-M following STIM1/2 KD in the absence of extracellular calcium. RM one-way ANOVA revealed no significant differences in either the AUC (Supplemental Fig. S4A, Holm–Sidak’s post-hoc tests, p = 0.1) or maximum amplitude (Supplemental Fig. S4B, p > 0.4) of ER store release following STIM KD compared to control cells, indicating that STIM silencing did not influence basal ER calcium store content or the extent of ER-calcium depletion following Gq stimulation.

We next sought to investigate the effects of STIM1 and STIM2 KD and their roles in regulation of ligand induced Ca2+ oscillations in the presence of extracellular calcium. While STIM1 KD induced a greater reduction in Ca2+ release following Oxo-M treatment, knockdown of STIM1 or STIM2 significantly attenuated the magnitude of Ca2+ release (Fig. 2F; linear model with Tukey’s HSD posttest, p < 0.0001, n = 4 human samples). Intriguingly, STIM2 KD also resulted in a significant reduction in the frequency of Ca2+ oscillations (Fig. 2G; STIM2: p = 0.002; STIM1/2: p = 0.0323) while STIM1 KD had no effect (STIM1: p = 0.7236). We also observed that neither STIM1 KD nor STIM2 KD altered the percentage of oscillatory responsive cells (Supplemental Fig. S5A, RM one-way ANOVA, p = 0.45) or the maximum oscillatory peak amplitude (Supplemental Fig. S5B, p = 0.1). Interestingly, the oscillatory response duration of Oxo-M induced calcium responses increased following STIM2 KD (p < 0.01) and 2-APB treatment (p < 0.0001) compared to control cells (Supplemental Fig. S5C). In summary, these results suggest that STIM1 is required for Gqα-induced SOCE while STIM2 specifically modulates the frequency of Ca2+ oscillations following ligand-mediated SOCE.

STIM2 is required for human oligodendrocyte progenitor differentiation. To determine whether STIM-dependent calcium oscillations may directly contribute to muscarinic M1q-R-mediated inhibition of hOPC differentiation, we assessed the independent effects of STIM1 and STIM2 siRNA treatment and their interactions with Oxo-M treatment on hOPC differentiation in vitro by three-way ANOVA (Fig. 3A). As shown previously15, Oxo-M treatment significantly blocked differentiation into O4+ immature OLs (F(1,3) = 14.31, p = 0.032, n = 4 human samples). Both siRNA control and STIM1 siRNA transfected hOPCs showed reduced differentiation in response to Oxo-M (Fig. 3B; Holm–Sidak’s post-hoc test, control: p = 0.006; STIM1: p = 0.015). Interestingly, STIM2 siRNA transfection alone or in combination with STIM1 abolished the anti-differentiative effects of Oxo-M (p > 0.2). This is consistent with a role of STIM2 downstream of Oxo-M mediated signaling.

In addition to Oxo-M dependent effects, STIM2 siRNA alone caused a significant reduction in O4+ OL differentiation (RM three-way ANOVA, STIM2 main effect F(1,3) = 28.64, p = 0.013, n = 4 human samples) while STIM1 siRNA had no effect (p = 0.42). In the absence of Oxo-M, we observed a significant decrease in O4+ OL differentiation cells following STIM2 siRNA transfection relative to siControl (p = 0.002). Interestingly, this effect was not observed when STIM1/2 siRNA were combined (p > 0.05). These results suggested that STIM2 signaling in the absence of Gqα agonist regulates hOPC differentiation and is required for the anti-differentiative effects of muscarinic agonism. We further examined the effect of STIM1/2 on morphological maturation by assessing the proportion of O4+ cells with simple or complex process elaboration as described47 (Supplemental Fig. S6A). STIM1/2 KD did not influence the percentage of simple O4+ oligodendrocytes (3-way ANOVA, p > 0.3). Oxo-M reduced the proportion of complex O4+ cells following transfection with either control or STIM1 siRNA but did not influence complex O4+ cell number following STIM2 KD (Holm–Sidak’s post-hoc test, p > 0.05).
p < 0.05) (Supplemental Fig. S6C). Interestingly, in the absence of Oxo-M, STIM2 KD reduced the percentage of complex O4+ cells (Holm–Sidak’s post-hoc test, p = 0.0013), while STIM1 KD had no effect (p = 0.61).

As differentiation and OPC proliferation are intimately linked, we next examined whether ER calcium sensors STIM1/2 influenced hOPC proliferation. We quantified the proportion of dividing Ki67+ OPCs following transfection with STIM1/2 siRNA or control siRNA (Fig. 3C). Similar to previous observations15, Oxo-M had no effect on hOPC proliferation. STIM1 or STIM2 siRNA treatment did not significantly influence proliferation

**Figure 4.** OptoSTIM drives oscillatory calcium responses in hOPCs in the absence of Gαq-coupled signaling. hOPCs were infected with OptoSTIM and jRCaMP1a lentiviruses to induce SOCE and observe calcium responses simultaneously. Cells were cultured in a temperature/CO2 controlled chamber during time-lapse fluorescence microscopy. Blue light (488 nm) excitation was used to induce SOCE at distinct frequencies using 5 min (3.33 mHz) or 30 min (0.55 mHz) stimulation intervals respectively. Blue light exposures were matched to ensure an equivalent amount of blue light stimulation across conditions (330 and 2000 ms per stimulus, respectively). Changes in intracellular Ca2+ concentration were assessed by jRCaMP1a fluorescence every 20 s. (A) Representative integrated calcium response to OptoSTIM-induced SOCE in the absence of Gαq-receptor activation. Images shown represent total fluorescence across 2.5 h of stimulation following a 30-min baseline period. (B) jRCaMP1a traces of mean ± SEM (blue shading) normalized calcium responses to 0.55 mHz and 3.33 mHz frequencies over the course of 2.5 h following a 30 m baseline with no stimulation (n ≥ 50 cells from a single representative biological replicate). SOCE was robustly induced throughout the imaging period and directly corresponded with the timing of blue light stimulation (vertical blue lines in middle and lower traces). (C) Quantification of integrated calcium responses at different stimulation frequencies measured for the duration of the stimulation period. Mean ± SEM of results from three independent experiments (n = 3 independent human fetal sample preparations) with > 50 cells analyzed per condition/replicate. *p < 0.05, RM one-way ANOVA with Holm–Sidak’s post-hoc test. Scale: 50 µm.
Figure 5. SOCE is sufficient to block hOPC differentiation and promote hOPC mitosis. Matched cultures of primary hOPCs were infected with OptoSTIM lentivirus and imaged for 2–3 days in an on-stage temperature/CO₂ controlled chamber. Bright field images were acquired every 5 min. OptoSTIM-mediated SOCE was induced with intermittent 488 nm excitation (5 s or 30 s interval for 330 ms and 2000 ms duration, respectively). (A) hOPC proliferation was quantified by counting mitotic events (white arrowheads). (B) The cumulative proportion of cells undergoing mitosis was quantified over 36 h following the onset of blue light stimulation. (C) Proliferation rates were normalized to the matched unstimulated condition. High frequency (3.33 mHz) OptoSTIM induction of SOCE resulted in a significant increase in hOPC mitotic events compared to control unstimulated and low frequency (0.55 mHz) stimulated hOPCs (n = 4 independent human fetal sample culture preparations). (D) The effect of OptoSTIM-induced SOCE on hOPC differentiation was determined by O4 immunocytochemistry (red) at 48 h post-stimulation. OptoSTIM transduced cells were identified by GFP expression which was uniform across experimental conditions (E). (F) Quantification of O4⁺ oligodendrocyte differentiation following OptoSTIM-induced SOCE (% O4⁺/GFP⁺). (G) Analysis of O4⁺ morphological maturation. High frequency (3.33 mHz) SOCE induced a significant reduction in O4⁺ cells as well as a significant reduction in complex branching morphology relative to control hOPCs. *p < 0.05, Holm–Sidák's post-hoc test. Mean ± SEM shown for each panel (n = 4 independent human fetal samples). Scale: 25 µm.
Optogenetically-induced SOCE blocks hOPC differentiation and promotes proliferation. Our previous results suggest that STIM1/2 mediated SOCE may be required for sustained calcium release following Gαq stimulation and thereby contribute to muscarinic inhibition of differentiation. We therefore sought to test whether oscillatory calcium SOCE directly regulates hOPC development. For this end, we expressed an optogenetically controllable STIM protein in hOPCs to enable blue-light control of SOCE in the absence of Gαq ligand stimulation. Following infection with lentiviral OptoSTIM, hOPCs were transduced with lentiviral jRCaMP1a, a red-shifted calcium indicator, to simultaneously measure intracellular Ca²⁺ while inducing SOCE. Blue light activation of OptoSTIM resulted in a consistent and robust oscillatory calcium influx which could be sustained for several hours in a frequency-specific manner (Fig. 4A,B). To avoid summation of OptoSTIM-induced Ca²⁺ release and ensure a distinct oscillatory wave form, based on the dissociation kinetics of OptoSTIM, we selected an upper frequency of 3.33 mHz to model that of 10 mHz waves observed following muscarinic receptor activation. As a control, we selected a lower frequency of 0.55 mHz which is below the lower threshold associated with frequency-dependent decoding in other non-excitatory cells. We matched the total blue-light exposure over time between frequencies by pulsing for 330 and 2000 ms at 3.33 and 0.55 mHz respectively. Based on jRCaMP1a imaging, oscillatory SOCE could be maintained for at least 3 h in hOPCs in vitro and was clearly observable at 18 h with 2000 ms pulses without loss of signal (Fig. 4B, n = 3 human samples). Importantly, we found that the total calcium release defined by AUC over the 2.5 h period was equivalent between groups (Fig. 4C; RM one-way ANOVA, Holm–Sidak’s post-hoc test, p = 0.49). As such, we could assess frequency dependent SOCE effects while controlling for total calcium flux.

We examined the effect of optogenetically-induced oscillatory SOCE on hOPC proliferation and differentiation (Fig. 5). Using time lapse microscopy and concurrent intermittent blue-light stimulation to induce SOCE, we assessed the number of mitotic events (Fig. 5A) to ascertain in the presence of both high and low frequency OptoSTIM1-induced SOCE. Induction of high frequency (3.33 mHz) oscillatory calcium entry produced a clear increase in the number of cumulative mitotic events at 24 h and 36 h post stimulation respectively (Fig. 5B, quantified in Fig. 5C; RM one-way ANOVA with Holm–Sidak’s post-hoc test, p = 0.006, n = 4 human samples). At 36 h of stimulation, high frequency SOCE resulted in a 40% increase rate of cell division relative to unstimulated control hOPCs (3.33 mHz: 25.6 ± 4.9% vs. control: 19.1 ± 4.7%, p = 0.014) (Fig. 5C). In contrast, low frequency SOCE had no effect on proliferation (0.55 mHz: 17.6 ± 5.9%, p = 0.38). Next, we investigated the effects of long term OptoSTIM induction on hOPC differentiation (Fig. 5D). We observed no gross alterations in transduced cell number following blue-light stimulation (Fig. 5E; RM one-way ANOVA with Holm–Sidak’s post-hoc test, p = 0.90, n = 4 human samples). Importantly, induction of high frequency SOCE substantially impaired hOPC differentiation by 50% relative to unstimulated control hOPCs (Fig. 5F; 3.33 mHz: 7.5 ± 1.7% vs. control: 16.6 ± 3.4%, p = 0.02). Differentiation by hOPCs which received induction of low frequency SOCE was not significantly different from unstimulated control cells (0.55 mHz: 12.83 ± 3.3%). Moreover, there was a significant reduction in the number of O4⁺ cells with complex branch morphology (> 3 processes) following 3.33 mHz stimulation compared to control cells (Fig. 5G; RM one-way ANOVA with Holm–Sidak’s post-hoc test, p = 0.04). This suggests that induction of oscillatory SOCE was sufficient to inhibit hOPC morphological maturation. Collectively these results indicate that sustained high frequency oscillatory SOCE was sufficient to block both hOPC differentiation and augment hOPC proliferation.

Discussion
In the present study, we demonstrate that a subset of Gαq-receptors expressed by human primary OPCs, including muscarinic M₁ and M₅ receptors, M₁₇-R, and metabotropic-glutamate-receptor-5 (mGluRS), induce prolonged oscillatory calcium signaling and that the ability to induce oscillatory calcium signaling correlated with their capacity to block differentiation. We found that a shared mechanism downstream muscarinic Gαq-receptor induced oscillatory signaling was the activation of store operated calcium entry (SOCE). Inhibition with SOCE antagonists or knockdown of ER-localized SOCE calcium sensors STIM1/2 reduced the magnitude of calcium signaling induced by muscarinic agonist stimulation. STIM2 ablation selectively reduced calcium oscillation frequency and spontaneous OL differentiation in vitro and, unlike control OPCs, treatment with muscarinic ligand did not further reduce differentiation following STIM2 knockdown. While SOCE exerted a major influence on calcium oscillations, as these experiments were performed using constant Gαq-receptor agonist exposure, we cannot exclude the requirement of IP₃-mediated release for the maintenance of prolonged calcium oscillations. Together, these data suggested a functional linkage between muscarinic receptor signaling and SOCE. Using an optogenetic approach to selectively activate SOCE in OPCs, we found that SOCE was sufficient to modulate OL differentiation in the absence of Gαq dependent signaling suggesting that SOCE is a key facet that impairs OL differentiation and remyelination. Furthermore, the frequency of SOCE rather than the overall amount of calcium influx due to SOCE was found to be vital in mediating the effect of calcium entry on differentiation and proliferation. This suggests that the calcium pathway includes frequency-dependent ‘decoders’ which regulate OL differentiation and that modulation of calcium frequency might represent an important mechanism by which diverse signals are integrated by parenchymal OPCs. In drug development, G-protein coupled receptors (GPCRs) are attractive candidates for therapeutic intervention and recently many small molecules that target GPCRs have been identified that modulate GPCR function and OL differentiation to promote myelin repair. For example, GPR17 which largely couples via Gαq, was found to negatively regulate GPCR differentiation while knockout was observed to promote remyelination. Muscarinic
receptor antagonists have displayed a remarkable capacity to improve OL differentiation and remyelination in various animal models. Using genetic approaches, the effects of these drugs have been localized to M₁R and M₃R. Both of these receptors represent canonical Gα₉-coupled receptors. Indeed, when Ga coupling was systematically analyzed across different subunits, M₁R displayed exquisite selectivity for rapid activation for Gα₁₁/Gα₁₃ coupling. In this study, we focused on Gα₉-coupled receptors to determine if a shared characteristic of Gα₉ receptors could be used to predict their ability to promote efficient OL differentiation and thereby impair remyelination. We analyzed RNA-seq analysis of primary hOPC to identify those Gα₉-coupled receptors expressed at the mRNA level and hypothesized that receptor-specific ligand activation would produce canonical oscillatory calcium signaling and block hOPC differentiation. Surprisingly, only a small subset of pharmacological Gα₉ ligands were capable of inducing prolonged calcium oscillation in hOPCs and this correlated with the ability of ligands to effectively block OL differentiation. CHPG, which activates mGluR₅, in a highly selective manner, was the only other ligand capable of inducing calcium oscillations in a large fraction of hOPCs. The specificity of Gα₉-receptor mediated signaling is consistent with previous results which have shown that while endothelin (ET) agonist treatment induces a monotonic calcium response while metabotropic glutamate receptor agonists induce calcium oscillations. mGluR₅ couples primarily via Ga₉ and does not have appreciable activity at Ga₉. In a similar manner to M₁R, mGluR₅ mRNA was relatively highly expressed in rodent OPCs and down-regulated following differentiation. Herein, we found that treatment with CHPG resulted in a dose-dependent blockade of hOPC differentiation.

In contrast, the other Gα₉-coupled receptors that elicited calcium responses in OPCs induced calcium release that was either considerably shorter in duration and/or were largely monotonic in nature. These differences could be due to differences in overall level of expression and/or differences in receptor coupling. From a large-scale screen of G-protein coupling, we observed that many of these receptors were promiscuously coupled with other Gα₉ subunits. For example, sphingosine-1-phosphate receptor-1 (S1PR₁) was observed as primarily coupled via Ga₉ and Ga₅ with little evidence of Ga₉ coupling. This difference corresponded with the observed function difference following activation of S1PR1 which results in OL differentiation from human OPCs. Furthermore, endothelin-B receptor (ENDRB), thrombin receptor II (F2R) and purinergic receptor Y1 (P2RY1) also show promiscuous coupling with multiple Ga₉ proteins upon activation. Together this suggests that selectivity in coupling may determine the net influence on downstream signaling and the nature of the resultant calcium response. As the coupling of GPCRs to specific Ga proteins are not absolute and in many cases is promiscuous, we anticipate that biased ligands or antagonists capable of promoting or blocking coupling along specific pathways may represent optimal approaches to promote OPC differentiation.

The mechanisms which shape the calcium-response following ligand application are complex and likely dependent on multiple interacting proteins. Among these, Ga subunits form specific complexes with their cognate Gβγ proteins which possess their own signaling capability and modulate the signaling of Ga subunits they interact with. Among these, specific isoforms of phosphoinositide-3-kinase (PI3K) and adenylate cyclase, voltage-operated calcium channels (VOCC) and inwardly rectifying K⁺ channel can be regulated by Gβγ. Activation of PI3K/Akt, adenylate cyclase, and VOCCs are associated with promotion of OPC differentiation suggesting that Gβγ activation may counteract oscillatory calcium signaling. For muscarinic receptor signaling, in rat pituitary cells Ga₃ is necessary for the carbachol-mediated calcium current, while in a rat leukemia cell line Ga₃ and Ga₅ were more important in the regulation of this current. In primary hOPCs, Ga₄ ablation did not influence calcium signaling following Otxo-M treatment, though redundancy with Ga₁ and Ga₅ is possible as these subunits are expressed at substantially higher levels in human and mouse OPCs.

In addition to the Ga₃ subunit specific regulation, receptor-specific activation of regulators of G-protein signaling (RGS) proteins provide specificity for G-protein coupling and modulate the kinetics of second messenger activation. RGS proteins promote termination of GPCR signaling via GTPase activation and prevent GPCR signaling in the absence of ligand. Following ligand activation and elevated Ca²⁺, RGS proteins exhibit a cyclical pattern of association with phosphatidylinositol-3,4,5-trisphosphate (PIP₃) and activated calcium/calmodulin (Ca²⁺/CaM) followed by re-association with the GPCR complex after Ca²⁺ levels return to baseline. This allows a second cycle to start and initiate another calcium spike. The kinetics of these steps, especially the slow dissociation of RGS protein from Ca²⁺/CaM, contributes to the resultant frequency of calcium oscillations. While the role of specific RGS proteins in the OPC and OL lineage is poorly understood, several RGS proteins are expressed in OPCs. Among these, RGS4 has been shown to be a potent negative regulator of muscarinic receptor signaling in insulinoma cells. Also noteworthy, the R7 family of RGS proteins (RGS6/7/9/11) form heterodimers with G-protein β subunit Gβ₃ (GNB5) which similarly attenuates M₁R-dependent Ca²⁺ signaling. Once activated, SOCE is associated with many cellular functions in neural progenitors such as proliferation and differentiation. In OPCs, SOCE can modulate PDGF-AA induced OPC proliferation. However, given the known role of PI3K/Akt signaling downstream of PDGF receptor, SOCE is unlikely to be a critical component of PDGF signaling. Likewise, the cellular role of calcium oscillations in OPC soma is not yet known. Our data using optogenetic induction of SOCE strongly suggest that oscillatory SOCE alone is sufficient to modulate both OPC proliferation and differentiation. While we were limited by the dissociation kinetics of OptoSTIM to an upper limit of 3.33 mHz stimulation, this frequency fits within the known frequencies of calcium oscillations in non-excitable cells and may recruit NEAT, NFXB and other downstream pathways. By matching total calcium influx during the period of exposure, we were able to demonstrate frequency dependence as a substantially lower frequency (0.55 mHz) was unable to modulate proliferation or differentiation. New approaches will be required to determine whether higher frequency SOCE can further alter these critical cellular processes.

SOCE itself is dependent on the association of CRAC subunit comprising STIM ER-calcium sensors and ORAI channel subunits. While STIM1 and STIM2 contributed to different aspects of muscarinic-induced SOCE and sustained oscillatory calcium signaling in hOPCs, we found that only STIM2 knockdown reduced spontaneous OL differentiation. Previous reports have found that apart from its role in agonist mediated SOCE, STIM2
signal often persists to a lesser degree in the absence of an ER-release stimulus. STIM2 responds to small fluctuations in ER calcium levels, and drives small local SOCE calcium entry when local calcium levels fall below baseline (reviewed in18). It is also known that STIM2 can regulate endogenous differentiation of other cell types through modulation of cytoplasmic calcium levels following STIM1-induced oscillatory SOCE59. Furthermore, small spontaneous SOCE calcium transients in the absence of spontaneous have been observed in mouse OPCs, and have been implicated in the regulation of differentiation60. It is possible, therefore, that STIM2 is required for these spontaneous transients and thus STIM2 KD may inhibit differentiation. In contrast, our data is consistent with prolonged oscillatory SOCE, either produced optogenetically or in response to M,R and mGluR agonists, causing a blockade of hOPC differentiation via global calcium-mediated changes. Additional studies will be necessary to test apart the specific mechanisms by which STIM2 directly influences oligodendrocyte differentiation.

The ER-calcium sensors STIM1/2 physically and functionally interact with one another to regulate SOCE. The relative abundance of STIM1 and STIM2 vary greatly between tissues and individual cell types. In human OPCs, STIM2 is more than threefold more abundant than STIM1 mRNA but both genes are relatively highly expressed (> 10 FPKM). In contrast, both STIM1 and STIM2 are expressed at equivalent levels in mouse OPCs. As the differences in the relative expression of STIM1/2 influences the resultant properties of SOCE in response to store depletion (reviewed in71), the differences in STIM1:STIM2 ratio in mouse and human may therefore underlie some of the species-specific functional differences in OPC behavior72. Both STIM1 and STIM2 have been shown to contribute to oscillatory SOCE in a context dependent manner73,74. Our data support a specific role of STIM2 in the regulation of OPC calcium oscillations and suggest that expression of STIM2 is required for muscarinic receptor induced differentiation blockade in hOPCs. Together with the direct regulation of OPC differentiation via optogenetically-gated SOCE, these data suggest that SOCE mediated via STIM activation will likely play an important role in mediating the negative effects of Gq-coupled receptors capable of blocking oligodendrocyte differentiation in health and disease.

Received: 14 May 2021; Accepted: 31 March 2022
Published online: 13 April 2022

References
1. Franklin, R. J. M. & Ffrench-Constant, C. Regenerating CNS myelin—From mechanisms to experimental medicines. Nat. Rev. Neurol. 18, 753–769. https://doi.org/10.1038/nrneurol.2017.136 (2017).
2. Faisnser, S., Plemel, J. R., Gold, R. & Yong, V. W. Progressive multiple sclerosis: From pathophysiology to therapeutic strategies. Nat. Rev. Drug Discov. 18, 905–922. https://doi.org/10.1038/s41573-019-0035-2 (2019).
3. Kühmann, T. et al. Differentiation block of oligodendroglial progenitor cells can cause for remyelination failure in chronic multiple sclerosis. Brain 131, 1749–1758. https://doi.org/10.1093/brainawt096 (2008).
4. Wolswijk, G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurol. 198, 601–609 (1998).
5. Thornton, M. A. & Hughes, E. G. Neuron-oligodendroglia interactions: Activity-dependent regulation of cellular signaling. Neuroscientist 22, 134916. https://doi.org/10.1172/jci.insight.123434 (2019).
6. Ortiz, E. C. et al. Neuronal activity in vivo enhances functional myelin repair. JCI Insight 5, e124343. https://doi.org/10.1172/jci.insight.124343 (2019).
7. Gautier, H. O. et al. Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyte progenitors. Nat. Commun. 6, 8518. https://doi.org/10.1038/ncomms9518 (2015).
8. Bernstein, M., Lyons, S. A., Moller, T. & Kettenmann, H. Receptor-mediated calcium signalling in glial cells from mouse corpus callosum slices. J. Neurosci. Res. 46, 152–163. https://doi.org/10.1002/jnr.10115 (1996).
9. Paez, P. M. & Lyons, D. A. Calcium signaling in the oligodendrocyte lineage: Regulators and consequences. Annu. Rev. Neurosci. 43, 163–186. https://doi.org/10.1146/annurev-neuro-100719-093050 (2020).
10. Berridge, M. J. & Irvine, R. F. Inositol phosphates and cell signalling. Nature 368, 866–873. https://doi.org/10.1038/368866a0 (1994).
11. Mei, F. et al. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife 5, e18246. https://doi.org/10.7554/eLife.18246 (2016).
12. Welliver, R. R. et al. Muscarinic receptor M3R signaling prevents efficient remyelination by human and mouse oligodendroglial progenitor cells. J. Neurosci. 38, 6921–6932. https://doi.org/10.1523/JNEUROSCI.1862-17.2018 (2018).
13. Mei, F. et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat. Med. 20, 954–960. https://doi.org/10.1038/nm.3618 (2014).
14. Deshmukh, V. A. et al. A regenerative approach to the treatment of multiple sclerosis. Nature 502, 327–332. https://doi.org/10.1038/nature12847 (2013).
15. Abiraman, K. et al. Anti-muscarinic adjunct therapy accelerates functional human oligodendrocyte repair. J. Neurosci. 35, 3676–3688. https://doi.org/10.1523/JNEUROSCI.3510-14.2015 (2015).
16. Gadea, A., Aguirre, A., Haydar, T. F. & Gallo, V. Endothelin-1 regulates oligodendrocyte development. J. Neurosci. 29, 10047–10062. https://doi.org/10.1523/JNEUROSCI.0822-09.2009 (2009).
17. Agresti, C. et al. ATP regulates oligodendroglial progenitor migration, proliferation, and differentiation: Involvement of metabotropic P2 receptors. Brain Res. Brain Res. Rev. 48, 157–165. https://doi.org/10.1016/j.brainresrev.2004.12.005 (2005).
18. Takeda, M., Nelson, D. J. & Soliven, B. Calcium signaling in cultured rat oligodendrocytes. Glia 14, 225–236. https://doi.org/10.1002/gra.40140308 (1995).
19. Luyt, K., Varadi, A., Durant, C. F. & Molnar, E. Oligodendroglial metabotropic glutamate receptors are developmentally regulated and involved in the prevention of apoptosis. J. Neurochem. 99, 641–656. https://doi.org/10.1111/j.1471-4159.2006.04103.x (2006).
20. Fun, L. W. et al. Exposure to serotonin adversely affects oligodendrocyte development and myelination in vitro. J. Neurochem. 133, 332–343. https://doi.org/10.1111/jnc.12988 (2015).
21. Jung, C. et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55, 1656–1667. https://doi.org/10.1002/glia.20576 (2007).
22. Chattopadhyay, N. et al. Calcium receptor expression and function in oligodendrocyte commitment and lineage progression: Potential impact on reduced myelin basic protein in CaR-null mice. J. Neurosci. Res. 66, 2159–2167. https://doi.org/10.1002/jnr.21662 (2008).
62. Luo, X., Popov, S., Berz, A. K., Wilkie, T. M. & Mualllem, S. RGS Proteins provide biochemical control of agonist-evoked [Ca2+]i oscillations. Mol. Cell. 7, 651–660. https://doi.org/10.1016/S0979-7655(01)00211-8 (2001).

63. Ruiz de Azua, I. et al. RGS4 is a negative regulator of insulin release from pancreatic β-cells in vitro and in vivo. Proc. Natl. Acad. Sci. 107, 7999–8004. https://doi.org/10.1073/pnas.1003655107 (2010).

64. Karpinsky-Semer, D., Volmar, C. H., Brothers, S. P. & Slepak, V. Z. Differential effects of the G95-RGS7 complex on muscarinic M3 receptor-induced Ca2+ influx and release. Mol. Pharmacol. 85, 758–768. https://doi.org/10.1124/mol.114.9191843 (2014).

65. Domenichini, E. et al. Store-operated calcium entry controls neural stem cell self-renewal in the adult brain subventricular zone. Stem Cells 36, 761–774. https://doi.org/10.1002/stem.2786 (2018).

66. Forostyak, O. et al. Physiology of Ca(2+) signalling in stem cells of different origins and differentiation stages. Cell Calcium 59, 57–66. https://doi.org/10.1016/j.ceca.2016.02.001 (2016).

67. Gopurappilly, R., Deb, B. K., Chakraborty, P. & Hasan, G. Stable STIM1 knockdown in self-renewing human neural precursors promotes premature neural differentiation. Front. Mol. Neurosci. 11, 178. https://doi.org/10.3389/fnmol.2018.00178 (2018).

68. López, E., Salido, G. M., Rosado, J. A. & Berna-Erro, A. Unraveling STIM2 function. J. Physiol. Biochem. 68, 619–633. https://doi.org/10.1007/s13105-012-0163-1 (2012).

69. Darbellay, B. et al. Human muscle economy myoblast differentiation and excitation-contraction coupling use the same molecular partners, STIM1 and STIM2. J. Biol. Chem. 285, 22437–22447. https://doi.org/10.1074/jbc.M110.118994 (2010).

70. Rui, Y., Pollitt, S. L., Myers, K. R., Feng, Y. & Zheng, J. Q. Spontaneous local calcium transients regulate oligodendrocyte development in culture through store-operated Ca(2+) entry and release. eNeura. https://doi.org/10.1523/ENEURO.0347-19.2020 (2020).

71. Berna-Erro, A., Jardin, I., Salido, G. M. & Rosado, J. A. Role of STIM2 in cell function and physiopathology. J. Physiol. 595, 3111–3128. https://doi.org/10.1113/jp273889 (2017).

72. Dietz, K. C., Polanco, J. J., Pol, S. U. & Sim, F. J. Targeting human oligodendrocyte progenitors for myelin repair. Exp. Neurol. 283, 489–500. https://doi.org/10.1016/j.expneurol.2016.03.017 (2016).

73. Kar, P., Bakowski, D., Di Capite, J., Nelson, C. & Parekh, A. B. Different agonists recruit different stromal interaction molecule proteins to support cytoplasmic Ca2+ oscillations and gene expression. Proc. Natl. Acad. Sci. U.S.A. 109, 6969–6974. https://doi.org/10.1073/pnas.1201240109 (2012).

74. Thiel, M., Lis, A. & Penner, R. STIM2 drives Ca2+ oscillations through store-operated Ca2+ entry caused by mild store depletion. J. Physiol. 591, 1433–1445. https://doi.org/10.1113/jphysiol.2012.245399 (2013).

75. Harriss, D. R., Marsh, K. A., Birmingham, A. T. & Hill, S. J. Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J. Urol. 154, 1241–1245 (1995).

76. Doherty, A. J., Palmer, M. J., Henley, J. M., Collingridge, G. L. & Jane, D. E. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36, 265–267. https://doi.org/10.1016/s0028-3908(97)00001-4 (1997).

77. Pennington, L. D. et al. 4-Methoxy-N-[2-( trifluoroethyl) biphenyl-4-ylcarbamoyl] nicotinamide: A potent and selective agonist of STP1. ACS Med. Chem. Lett. 2, 752–757. https://doi.org/10.1021/ml2001399 (2011).

78. Vassallo, R. R. Jr., Kieber-Emmons, T., Cichowski, K. & Brass, L. F. Structure–function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J. Biol. Chem. 267, 6081–6085 (1992).

79. Calleri, E. et al. Frontal affinity chromatography–mass spectrometry useful for characterization of new ligands for GPR17 receptor. J. Med. Chem. 53, 3489–3501. https://doi.org/10.1021/jm090169y (2010).

80. Kawanabe, Y., Okamoto, Y., Enoki, T., Hashimoto, N. & Masaki, T. Ca(2+) channels activated by endothelin-1 in CHO cells expressing endothelin-A or endothelin-B receptors. Am. J. Physiol. Cell Physiol. 281, C1676–1685. https://doi.org/10.1152/ajpcell.2001.281.5.C1676 (2001).

81. Chhatwal, M. et al. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J. Pharmacol. Exp. Ther. 311, 1038–1043. https://doi.org/10.1124/jpet.104.068650 (2004).

82. McGuire, J. J., Safieddine, M., Trigg, C. R., Sun, K. & Hollenberg, M. D. 2-furanyl-LIGRLO-amide: A potent and selective proteinase-activated receptor 2 agonist. J. Pharmacol. Exp. Ther. 309, 1124–1131. https://doi.org/10.1124/jpet.103.064584 (2004).

83. Taburean, I. V. Functional pharmacology of H1 histamine receptors expressed in mouse preoptic/anterior hypothalamic neurons. Br. J. Pharmacol. 170, 415–425. https://doi.org/10.1111/bph.12286 (2013).

84. Console-Bram, L., Brailoiu, E., Brailoiu, G. C., Sharir, H. & Aboud, M. E. Activation of GPR18 by cannabinoid compounds: A tale of biased agonism. Br. J. Pharmacol. 171, 3908–3917. https://doi.org/10.1111/bph.12746 (2014).

85. Hinz, S., Lacher, S. K., Seibt, B. F. & Muller, C. E. BAY60-6583 acts as a partial agonist at adenosine A2B receptors. J. Pharmacol. Exp. Ther. 349, 427–436. https://doi.org/10.1124/jpet.113.210849 (2014).

86. Meis, S. et al. NS456 (4′-{carboxy[4-methyl-phenylene]-car-bonylmino}-3-{4′(methyl-phenylene)-car-bonylmino})-bis(1,3- xylene-alpha, alpha′-diphosphonic acid) tetrasodium salt is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-dendritic cells. J. Pharmacol. Exp. Ther. 332, 238–247. https://doi.org/10.1124/jpet.109.1577750 (2010).

Acknowledgements

This work was supported by grants from the NINDS (R01NS104021), the National Multiple Sclerosis Society (RG 5505-A-2, RG 5110A1/1), the Kalec Multiple Sclerosis Foundation, the Ms Change Foundation, and the SK Foundation. J.P. received support from NIGMS (R01GM09554002), NICATS (UL1TR001412-S1). J.P and R.A.S received support from NYSTEM Stem Cells in Regenerative Medicine Fellowship (#C302090). In addition, we would like to acknowledge the assistance of the Confocal Microscope and Flow Cytometry Facility in the School of Medicine and Biomedical Sciences, University at Buffalo and thank Dr. Pablo Paz for advice with calcium imaging of OPCs.

Author contributions

R.S., H.K., J.P and J.B. performed in vitro experiments with human cells. R.S. and F.S. prepared figures, analyzed data and wrote the main manuscript text.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-10095-1.
